fda compounding semaglutide enforcement november 2025 news Beyond the Headlines: Warning Letters to GLP-1 Compounders FDA's GLP-1 decision kicks off

The SUSTAIN-6 trial showed that semaglutide has acute pancreatitis rates similar to placebo controls

However, the current landscape differs significantly from peak shortage periodsand compounded options through licensed 503A pharmacies continue to provide reliable access for patients seeking weight loss and metabolic support

Insulin is a hormone produced by the pancreas that regulates blood glucose (sugar) levels, allowing sugar to move from the bloodstream into cells to produce energy

Cureus, 15(7), e42153

00:08:27 Vickie Danaher So these are really important points that should be shared with patients picking up oral semaglutide at our pharmacies or patients like Jay who are thinking about switching from injectable to oral semaglutide